CA2500978A1 - Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations - Google Patents
Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations Download PDFInfo
- Publication number
- CA2500978A1 CA2500978A1 CA002500978A CA2500978A CA2500978A1 CA 2500978 A1 CA2500978 A1 CA 2500978A1 CA 002500978 A CA002500978 A CA 002500978A CA 2500978 A CA2500978 A CA 2500978A CA 2500978 A1 CA2500978 A1 CA 2500978A1
- Authority
- CA
- Canada
- Prior art keywords
- cea
- monovalent
- agent
- mediated
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne la différentiation et la tumorigénicité. L'invention concerne, plus particulièrement, des ligands ciblant un antigène carcinoembryonnaire humain (CEA) et CEACAM6 de sorte que les activités d'adhésion et d'inhibition de différentiation et les effets tumorigènes des membres CEA et CEACAM6 de la superfamille Ig peuvent être réduits ou bloqués. L'invention concerne également des agents de liaison de CEA qui inversent les effets tumorigènes à médiation CEA par dissociation de CEA et de CEACAM6. Dans un mode de réalisation, l'invention concerne des méthodes permettant de réduire, d'empêcher, de prévenir ou d'inverser un effet tumorigène à médiation CEA, qui consistent à utiliser un agent de dissociation de CEA réduisant l'effet tumorigène à médiation CEA. Dans un autre mode de réalisation, l'invention concerne des compositions et leurs utilisations permettant d'inverser les effets tumorigènes à médiation CEA sur des cellules cancéreuses humaines. L'application concerne, en particulier, un agent de liaison monovalent de CEA interférant avec une interaction CEA sensible à un effet tumorigène à médiation CEA, ce qui permet de réduire ou d'inverser lesdits effets.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41552002P | 2002-10-03 | 2002-10-03 | |
US60/415,520 | 2002-10-03 | ||
PCT/CA2003/001533 WO2004031238A2 (fr) | 2002-10-03 | 2003-10-03 | Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2500978A1 true CA2500978A1 (fr) | 2004-04-15 |
Family
ID=32069871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002500978A Abandoned CA2500978A1 (fr) | 2002-10-03 | 2003-10-03 | Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1554309A2 (fr) |
AU (1) | AU2003278002A1 (fr) |
CA (1) | CA2500978A1 (fr) |
WO (1) | WO2004031238A2 (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5020636B2 (ja) | 2003-11-06 | 2012-09-05 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
JP5095391B2 (ja) * | 2004-04-20 | 2012-12-12 | スフィンゴテック・ゲーエムベーハー | 医療診断におけるタキキニンの前駆体および/またはその断片の使用 |
EP2286844A3 (fr) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Conjugués anticorps-médicament et procédés |
CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
IN2012DN03025A (fr) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
CA2816426A1 (fr) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Conjugues d'anticorps alaninyl-maytansinol |
CA2833212C (fr) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre |
CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
WO2013130093A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline |
CA2941485C (fr) | 2012-10-12 | 2018-06-12 | Philip Wilson Howard | Pyrrolobenzodiazepines et leurs conjugues |
EP2906297B1 (fr) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Conjugués anticorps - pyrrolobenzodiazépine |
SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
WO2014057114A1 (fr) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Conjugués pyrrolobenzodiazepine-anticorps anti-psma |
JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
WO2014057113A1 (fr) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Conjugués anticorps anti-psma - pyrrolobenzodiazépine |
JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドMedImmune Limited | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
EP2968585B1 (fr) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazépines et leurs conjugués |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
MX2016001862A (es) | 2013-08-12 | 2016-08-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento. |
EP3054986B1 (fr) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépine |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052534A1 (fr) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Conjugués anticorps-pyrrolobenzodiazépine |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック, インコーポレイテッド | 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
WO2015095223A2 (fr) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci |
EP3082875B1 (fr) | 2013-12-16 | 2020-11-25 | Genentech, Inc. | Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
EP3388449A3 (fr) | 2014-09-12 | 2018-10-24 | F. Hoffmann-La Roche AG | Anticorps et conjugués modifies génetiquement avec de la cystéine |
JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック, インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017201449A1 (fr) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Conjugués anticorps-protac et procédés d'utilisation |
WO2017205741A1 (fr) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site |
JP7043425B2 (ja) | 2016-06-06 | 2022-03-29 | ジェネンテック, インコーポレイテッド | シルベストロール抗体-薬物コンジュゲート及び使用方法 |
EP3496763A1 (fr) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci |
WO2018065501A1 (fr) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Procédés de préparation de conjugués anticorps-médicament |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
LT3544636T (lt) | 2017-02-08 | 2021-06-25 | Adc Therapeutics Sa | Pirolobenzodiazepino-antikūno konjugatai |
HUE059828T2 (hu) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pirrolobenzodiazepin konjugátumok |
EP3612234B1 (fr) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Polythérapie avec un conjugué anticorps anti-axl-médicament |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
AU2018316532B2 (en) | 2017-08-18 | 2022-11-24 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
SG11202001907QA (en) | 2017-09-20 | 2020-04-29 | Ph Pharma Co Ltd | Thailanstatin analogs |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
WO2020086858A1 (fr) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
PT584368E (pt) * | 1992-02-14 | 2002-10-31 | Suntory Ltd | Utilizacao e processo para a producao de um inibidor de metasteses e um inibidor de adesao celular contendo respectivamente um anticorpo |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
WO1999041370A1 (fr) * | 1998-02-12 | 1999-08-19 | Mcgill University | Therapie anticancereuse par differenciation a base de cea/nca |
US6774209B1 (en) * | 2000-04-03 | 2004-08-10 | Dyax Corp. | Binding peptides for carcinoembryonic antigen (CEA) |
AU2002305068A1 (en) * | 2001-03-21 | 2002-10-08 | The Trustees Of Boston University | Compositions and methods to prevent metastasis from primary malignancies |
-
2003
- 2003-10-03 EP EP03769082A patent/EP1554309A2/fr not_active Withdrawn
- 2003-10-03 WO PCT/CA2003/001533 patent/WO2004031238A2/fr not_active Application Discontinuation
- 2003-10-03 CA CA002500978A patent/CA2500978A1/fr not_active Abandoned
- 2003-10-03 AU AU2003278002A patent/AU2003278002A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004031238A3 (fr) | 2004-07-29 |
AU2003278002A8 (en) | 2004-04-23 |
AU2003278002A1 (en) | 2004-04-23 |
WO2004031238A2 (fr) | 2004-04-15 |
EP1554309A2 (fr) | 2005-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2500978A1 (fr) | Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations | |
JP2022104941A (ja) | ヒト化抗cd73抗体 | |
CN109942712B (zh) | 抗pd-l1/vegf双功能抗体及其用途 | |
KR20220064986A (ko) | 항-pd-l1 단일-도메인 항체 및 그의 유도체 및 용도 | |
CN114230667A (zh) | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 | |
JP2012507299A (ja) | Light標的分子およびその使用 | |
US20230203200A1 (en) | Recruiting agent further binding an mhc molecule | |
CN113423736B (zh) | 对muc18特异性的抗体 | |
CN107849138B (zh) | 抗Aggrus单克隆抗体及其应用 | |
CN113348180A (zh) | Ox40抗体及其制备方法和应用 | |
JP2022523710A (ja) | Cd44に特異的な抗体 | |
JP2022514786A (ja) | Muc18に特異的な抗体 | |
CN113045659B (zh) | 抗cd73人源化抗体 | |
CN115768797A (zh) | 抗b7-h3抗体及其制备和应用 | |
JP2022548777A (ja) | マウスおよびヒト線維芽細胞活性化タンパク質(fap)と交差反応するイヌ線維芽細胞活性化タンパク質に対するモノクローナル抗体 | |
EP3904384A1 (fr) | Anticorps anti-gitr complètement humanisé et son procédé de préparation | |
CN111378040B (zh) | 检测多种恶性肿瘤细胞的抗体及其应用 | |
US20060024314A1 (en) | Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics | |
KR102423942B1 (ko) | 항-tnfrsf25 항체 | |
US20200330591A1 (en) | Treatment | |
US20060051352A1 (en) | CEA binding agents and compositions to reverse CEA-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof | |
WO2021244587A1 (fr) | Protéine de fusion anti-pd-l1/tgf-ss | |
CN117396507A (zh) | 抗bcam抗体或其抗原结合片段 | |
CN116410313A (zh) | Cd30人源化鼠单抗开发 | |
CN117242097A (zh) | 一种抗egfr/vegf双功能融合蛋白及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |